Assessing Afya (NasdaqGS:AFYA) Valuation After Recent Share Price Weakness

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

Afya stock performance context

Afya (NasdaqGS:AFYA) has been drawing investor attention after a period in which the stock showed a 6.6% decline over the past month and a 6.2% decline over the past 3 months.

See our latest analysis for Afya.

That recent 6.6% 1 month share price decline sits alongside a year to date share price return of 6.5% decline and a 1 year total shareholder return of 23% decline, so shorter term momentum looks weaker even though the 3 year total shareholder return stands at 34% gain.

If you are weighing Afya against other opportunities in education and broader technology enabled sectors, it can help to widen the search and review 17 top founder-led companies

With Afya trading at $13.98 and an indicated intrinsic value gap plus a discount to analyst targets, the key question for you is simple: is this a genuine value opportunity or is the market already pricing in future growth?

Most Popular Narrative: 5.9% Undervalued

Afya's most followed narrative, according to NateF, points to a fair value of $14.86 against the last close of $13.98, suggesting modest undervaluation that hinges on specific growth and margin assumptions.

Afya’s growth prospects are underpinned by strong demand for healthcare professionals, regulatory tailwinds in medical education, and opportunities in digital transformation. However, risks such as economic volatility, regulatory challenges, and increasing competition could impact its performance. Investors should closely monitor market dynamics, particularly Brazil’s economic conditions, regulatory policies, and technological advancements, to assess Afya’s potential as an investment over the next 1 to 3 years.

Read the complete narrative.

Curious what revenue path, profit margins, and medical seat expansion assumptions sit behind that fair value, and how digital health fits into the equation? The full narrative lays out the growth runway, the acquisition playbook, and the earnings profile that underpin the $14.86 figure in far more detail.

Result: Fair Value of $14.86 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this thesis can be challenged if Brazil’s economy weakens and squeezes student affordability, or if tighter regulation slows approvals for new medical seats.

Find out about the key risks to this Afya narrative.

Next Steps

With mixed sentiment across recent share performance and valuation narratives, this is a good moment to look at the numbers yourself and act before views shift further. To see the balance of concerns and potential upside in a single place, review the 5 key rewards and 1 important warning sign.

Story Continues

Looking for more investment ideas?

If Afya has you thinking more broadly about your portfolio, now can be a time to scan for other opportunities before the next wave of ideas gets crowded.

Spot potential high risk high reward setups early by reviewing the 21 elite penny stocks with strong financials that already pass strict financial filters. Zero in on quality companies on sale by checking the 48 high quality undervalued stocks before prices move closer to fair value. Strengthen the foundation of your portfolio by focusing on the solid balance sheet and fundamentals stocks screener (44 results) that can better handle shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AFYA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments